Compensated Awareness Post View
Disclaimer
YM BioSciences, Inc. (YMI) Begins Phase II Trial for Its CYT387 Drug
YM BioSciences Inc. is a drug development company. It is currently advancing three clinical stage products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2 kinases; CYT997, a vascular disrupting agent; and nimotuzumab, an EGFR-targeting monoclonal antibody.
The company today announced that it has enrolled the first of 60 patients in its Phase II trial of CYT387. The drug is to be administered twice daily for the treatment of myelofibrosis. The trial is intended to further evaluate the safety and tolerability of YM BioScienes’ JAK1/JAK2 inhibitor, as well as its efficacy in reducing spleen size, improving symptoms and reducing transfusion dependence in patients with the disease.
In an ongoing Phase I/II trial, CYT387 appears to have a favorable safety profile and has produced a clinically beneficial response in a number of patients. Initial data from this new trial will be used to further enhance YM BioSciences’ pivotal trial designs. The company will acquire additional safety and efficacy data for the drug at doses complementary to those evaluated in the ongoing 166 patient trial.
YM BioSciences’ president and CEO, Dr. Nick Glover, added, “The substantial volume of patient data from the combined studies will be an important component of any future marketing application.”
For more information on YM BioSciences and its CYT387 drug, please visit the company’s website at www.ymbiosciences.com
